• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

InflaRx (Group)

InflaRx is a biopharmaceutical company focusing on the development of new therapeutics controlling the inflammatory response based on its proprietary technology.. InflaRx has developed a pipeline of first-in-class antibodies directed against the terminal complement component C5a. While IFX-1 focuses on the acute care space, its product candidates, IFX-2 and IFX-3, are being developed in chronic inflammatory disease indications. InflaRx was founded in 2007 and is headquartered in Jena, Germany, with long standing research collaborations in the US and China. The team consists of renowned experts in complement research and clinical acute care. InflaRx is privately owned and financed by bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group and various international family offices. *

 

	Start	2007-01-01 established
	Industry	anti-inflammatory drug
	Industry 2	IFX-1 (InflaRx)
	Person	Riedemann, Niels C. (InflaRx 200803 Managing Director + founder)
	Person 2	Christ, Arnd (InflaRx 201506– CFO before Proteros + MediGene + NovImmune + Probiodrug + Hoechst)
	Region	Jena
	Country	Germany
	Street	2 Winzerlaer Str.
	City	07745 Jena
		Address record changed: 2017-11-13
Basic data	Employees	n. a.
	Currency	EUR
	Profit	-29,815,000 (2018-12-31)
	Cash	115,200,000 (2018-03-31)
		* Document for �About Section�: Merck & Co., Inc.. (1/11/16). "Press Release: Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program". Kenilworth, NJ.
		Record changed: 2019-06-03

Advertisement

More documents for InflaRx (Group)

• [1] InflaRx N.V.. (6/5/19). "Press Release: InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa". Jena....
• [2] InflaRx N.V.. (2/14/19). "Press Release: Richard Brudnick to Join InflaRx Board of Directors". Jena....
• [3] InflaRx N.V.. (2/6/19). "Press Release: InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa". Jena....
• [4] InflaRx N.V.. (1/3/19). "Press Release: InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management". Jena & New York, NY....
• [5] InflaRx N.V.. (11/21/18). "Press Release: InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results". Jena....
• [6] InflaRx N.V.. (11/8/18). "Press Release: InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa". Jena....
• [7] InflaRx N.V.. (9/21/18). "Press Release: InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors". Jena....
• [8] InflaRx N.V.. (6/5/18). "Press Release: InflaRx Opens New Research Facility in Ann Arbor". Jena....
• [9] InflaRx N.V.. (5/17/18). "Press Release: InflaRx N.V. Reports First Quarter 2018 Financial & Operating Results". Jena....
• [10] InflaRx N.V.. (5/8/18). "Press Release: InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shares". Jena....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.